Dexamethasone Intravitreal Implant (Ozurdex®) for Recurrent Vogt-Koyanagi-Harada (VKH) Disease Posterior Uveitis

Benha University16 enrolled

Overview

VKH disease is a vision threatening condition.The investigators consider that ozurdex intravitreal implant is an effective line of treatment in recurrent VKH posterior uveitis.

Baseline ,and postoperative 1 ,6 ,12 and 24 months full ophthalmic examination was done. Procedure included intravitreal injection of Dexamethasone implant 0.7 mg (Ozurdex(®); Allergan, Inc, Irvine, CA)

Study Type

OBSERVATIONAL

Enrollment

Conditions

Posterior Uveitis

Interventions

Dexamethasone Ophthalmic implantDRUG

intravitreal injection of ozurdex implant

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Recurrent VKH posterior uveitis Exclusion Criteria: * retinal pathology, other causes of posterior uveitis

Locations (1)

INMC

Abu Dhabi, United Arab Emirates

Outcomes

Primary Outcomes

Best corrected visual acuity (BCVA)

Change in BCVA

Time frame: 2 years

Secondary Outcomes

optical coherence tomography (OCT) foveal thickness

changes in central foveal thickness

Time frame: 2 years

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.